Literature DB >> 14573430

Using superparamagnetic iron oxide-enhanced MRI to differentiate metastatic hepatic tumors and nonsolid benign lesions.

Seishi Kumano1, Takamichi Murakami, Tonsok Kim, Masatoshi Hori, Atsuya Okada, Takashi Sugiura, Yumi Noguchi, Syuji Kawata, Kaname Tomoda, Hironobu Nakamura.   

Abstract

OBJECTIVE: We evaluated the ability of superparamagnetic iron oxide (SPIO)-enhanced MRI to differentiate solid metastatic tumors and nonsolid benign lesions by clarifying the characteristic signal-intensity pattern of each lesion on SPIO-enhanced T2-weighted and heavily T1-weighted gradient-echo images.
MATERIALS AND METHODS: SPIO-enhanced MRI was performed using a 1.5-T system in 33 consecutive patients without cirrhosis who had 81 focal hepatic lesions (42 cysts, 13 hemangiomas, 26 metastatic tumors). The relative signal intensity of lesions on SPIO-enhanced heavily T1- and T2-weighted gradient-echo images was classified into one of the following three categories: high intensity, isointensity, or low intensity relative to the surrounding liver parenchyma. The diagnostic accuracy for differentiating solid metastatic tumors from nonsolid benign lesions (cysts or hemangiomas) was determined.
RESULTS: A combination of the relative signal intensity of the lesion on T2- and heavily T1-weighted gradient-echo images could be classified into the following five categories: high intensity and high intensity (category 1), high intensity and isointensity (category 2), high intensity and low intensity (category 3), isointensity and isointensity (category 4), and isointensity and low intensity (category 5). According to these categories, category 1 contained two hemangiomas, category 2 had 11 hemangiomas, category 3 had 25 metastatic tumors and two cysts, category 4 had three cysts, and category 5 had 37 cysts and one metastatic tumor. When a tumor with a relative signal intensity of categories 1 or 2 was considered to be a hemangioma (category 3 metastatic tumors and categories 4 and 5 cysts), diagnostic accuracy for characterizing such hepatic lesions was 96% (78/81).
CONCLUSION: When evaluating metastatic liver tumors on SPIO-enhanced MRI, we recommend that heavily T1- and T2-weighted gradient-echo images be obtained with our parameters to exclude hemangiomas or cysts.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14573430     DOI: 10.2214/ajr.181.5.1811335

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  11 in total

Review 1.  [Current status of MRI diagnostics with liver-specific contrast agents. Gd-EOB-DTPA and Gd-BOPTA].

Authors:  C Stroszczynski; G Gaffke; M Gnauck; F Streitparth; G Wieners; E Lopez-Häninnen
Journal:  Radiologe       Date:  2004-12       Impact factor: 0.635

2.  Magnetite Nanoparticles for Medical MR Imaging.

Authors:  Zachary R Stephen; Forrest M Kievit; Miqin Zhang
Journal:  Mater Today (Kidlington)       Date:  2011-07       Impact factor: 31.041

3.  Detection of hepatic metastases by superparamagnetic iron oxide-enhanced MR imaging: prospective comparison between 1.5-T and 3.0-T images in the same patients.

Authors:  Keitaro Sofue; Masakatsu Tsurusaki; Mototaka Miyake; Aine Sakurada; Yasuaki Arai; Kazuro Sugimura
Journal:  Eur Radiol       Date:  2010-04-29       Impact factor: 5.315

4.  Differentiation of hepatic tumors by use of image contrast with T2-weighted MRI.

Authors:  Akio Ogura; Katsumi Hayakawa; Tosiaki Miyati; Fumie Maeda; Akira Miyai; Fumito Saeki; Takaharu Murata
Journal:  Radiol Phys Technol       Date:  2008-11-11

5.  Transparent magnetic photoresists for bioanalytical applications.

Authors:  Philip C Gach; Christopher E Sims; Nancy L Allbritton
Journal:  Biomaterials       Date:  2010-08-16       Impact factor: 12.479

6.  Evaluation of the changes in signals from the spleen using ferucarbotran.

Authors:  Tatsuya Gomi; Masashi Nagamoto; Mika Tsunoo; Shigehiko Terada; Hitoshi Terada; Ehiichi Kohda
Journal:  Radiat Med       Date:  2007-04-27

7.  USPIO-enhanced MR imaging of macrophage infiltration in native and transplanted kidneys: initial results in humans.

Authors:  Olivier Hauger; Nicolas Grenier; Colette Deminère; Catherine Lasseur; Yahsou Delmas; Pierre Merville; Christian Combe
Journal:  Eur Radiol       Date:  2007-05-22       Impact factor: 5.315

8.  MRI after magnetic drug targeting in patients with advanced solid malignant tumors.

Authors:  A-J Lemke; M-I Senfft von Pilsach; A Lübbe; C Bergemann; H Riess; R Felix
Journal:  Eur Radiol       Date:  2004-08-05       Impact factor: 5.315

9.  Resovist-enhanced MRI for preoperative assessment of colorectal hepatic metastases: a case of multiple bile duct hamartomas associated with colon cancer.

Authors:  Hiroshi Suzuki; Giichiro Tsurita; Soichiro Ishihara; Masaaki Akahane; Joji Kitayama; Hirokazu Nagawa
Journal:  Case Rep Gastroenterol       Date:  2008-12-10

10.  Active-target T1-weighted MR Imaging of Tiny Hepatic Tumor via RGD Modified Ultra-small Fe3O4 Nanoprobes.

Authors:  Zhengyang Jia; Lina Song; Fengchao Zang; Jiacheng Song; Wei Zhang; Changzhi Yan; Jun Xie; Zhanlong Ma; Ming Ma; Gaojun Teng; Ning Gu; Yu Zhang
Journal:  Theranostics       Date:  2016-07-15       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.